Literature DB >> 24900489

Measurement of atropisomer racemization kinetics using segmented flow technology.

Jennifer E Davoren1, Mark W Bundesmann1, Qi T Yan1, Elizabeth M Collantes1, Scot Mente1, Deane M Nason1, David L Gray1.   

Abstract

When stable atropisomers are encountered by drug discovery teams, they can have important implications due to potential differences in their biological activity, pharmacokinetics, and toxicity. Knowledge of an atropisomer's activation parameters for interconversion is required to facilitate informed decisions on how to proceed. Herein, we communicate the development of a new method for the rapid measurement of atropisomer racemization kinetics utilizing segmented flow technology. This method leverages the speed, accuracy, low sample requirement, safety, and semiautomated nature of flow instrumentation to facilitate the acquisition of kinetics data required for experimentally probing atropisomer activation parameters. Measured kinetics data obtained for the atropo isomerization of AMPA antagonist CP-465021 using segmented flow and traditional thermal methods were compared to validate the method.

Entities:  

Keywords:  Atropisomer; Reaction kinetics; Segmented flow chemistry

Year:  2012        PMID: 24900489      PMCID: PMC4025797          DOI: 10.1021/ml2003108

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  10 in total

1.  Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists.

Authors:  W M Welch; F E Ewing; J Huang; F S Menniti; M J Pagnozzi; K Kelly; P A Seymour; V Guanowsky; S Guhan; M R Guinn; D Critchett; J Lazzaro; A H Ganong; K M DeVries; T L Staigers; B L Chenard
Journal:  Bioorg Med Chem Lett       Date:  2001-01-22       Impact factor: 2.823

2.  Quinazolin-4-one alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists: structure-activity relationship of the C-2 side chain tether.

Authors:  B L Chenard; W M Welch; J F Blake; T W Butler; A Reinhold; F E Ewing; F S Menniti; M J Pagnozzi
Journal:  J Med Chem       Date:  2001-05-24       Impact factor: 7.446

3.  New chiral phosphorus ligands for enantioselective hydrogenation.

Authors:  Wenjun Tang; Xumu Zhang
Journal:  Chem Rev       Date:  2003-08       Impact factor: 60.622

4.  Modified BINAP: the how and the why.

Authors:  Mikaël Berthod; Gérard Mignani; Gary Woodward; Marc Lemaire
Journal:  Chem Rev       Date:  2005-05       Impact factor: 60.622

Review 5.  Chiral separations.

Authors:  Timothy J Ward
Journal:  Anal Chem       Date:  2006-06-15       Impact factor: 6.986

6.  Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist.

Authors:  J T Lazzaro; A V Paternain; J Lerma; B L Chenard; F E Ewing; J Huang; W M Welch; A H Ganong; F S Menniti
Journal:  Neuropharmacology       Date:  2002-02       Impact factor: 5.250

Review 7.  The challenge of atropisomerism in drug discovery.

Authors:  Jonathan Clayden; Wesley J Moran; Paul J Edwards; Steven R LaPlante
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

Review 8.  Assessing atropisomer axial chirality in drug discovery and development.

Authors:  Steven R Laplante; Lee D Fader; Keith R Fandrick; Daniel R Fandrick; Oliver Hucke; Ray Kemper; Stephen P F Miller; Paul J Edwards
Journal:  J Med Chem       Date:  2011-09-15       Impact factor: 7.446

9.  Revealing atropisomer axial chirality in drug discovery.

Authors:  Steven R LaPlante; Paul J Edwards; Lee D Fader; Araz Jakalian; Oliver Hucke
Journal:  ChemMedChem       Date:  2011-01-05       Impact factor: 3.466

10.  CP-465,022, a selective noncompetitive AMPA receptor antagonist, blocks AMPA receptors but is not neuroprotective in vivo.

Authors:  Frank S Menniti; Alistair M Buchan; Bertrand L Chenard; Donald J Critchett; Alan H Ganong; Victor Guanowsky; Patricia A Seymour; Willard M Welch
Journal:  Stroke       Date:  2003-01       Impact factor: 7.914

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.